AHA 2019: French Registry Data Favor Edwards’ Sapien TAVR Over Medtronic’s CoreValve
The study’s authors say head-to-head randomized trials of the latest transcatheter aortic valves are urgently needed
Registry data from France shows transcatheter aortic valve replacement patients have better outcomes with Edwards’ Sapien balloon-expandable valves than with Medtronic’s CoreValve self-expanding valves.
You may also be interested in...
Medtronic Announces Two New Trials To Expand TAVR Indications
The SMART trial will compare Medtronic’s Evolut TAVR systems to Edward’s Sapien 3 devices. Evolut EXPAND TAVR I will evaluate Evolut in patients with symptomatic moderate aortic stenosis or asymptomatic severe disease.
Abbott Receives CE Mark For FlexNav TAVR System
Abbott enters the highly competitive TAVR market with its newly CE-marked FlexNav delivery system for Portico.
Cardiovascular Sales & Earnings Roundup: Medtronic TAVR Disappoints While Abbott And Boston Scientific See Structural Success In 2019
The top five cardiovascular device companies, as ranked by Medtech Insight’s MTI 100, have reported their sales and earnings for the last quarter of the calendar year 2019. Here are the highlights from the most recent presentations from Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences and Terumo.